I agree with Respert, buttoning down the CRC protocol has
I agree with Respert, buttoning down the CRC protocol has taken time but it must be tight…now we know it’s coming even if it was not yesterday. A reminder the next catalyst will appear BEFORE the CRC study start, and it is likely to portend a seismic change in share price long before and CRC results would be filed. It is useful to take another look at the pipeline page just updated. For the uninitiated who may visit it from a PR as we received today there are several things that stand out after a quick glance:
1) Wow, what a broad suite of indications…cancer…multiple types!
2) Inflammation…again, multiple origins? Strong hints of platform molecule. Alzheimer’s!
3) Multiple trials already phase 2 and a successful trial from phase 3?!
4) Leronlimab to PREVENT AND/OR REVERSE liver inflammation. Preclinical, but the MASH mice, those still squeaking at the end of the study this September under the influence of Leronlimab have the potential to catapult direct to phase 2 under a partnership. If so, current share prices should be in the rear-view mirror. Remind yourself Cytodyn has already completed a phase 2 study for MASH in humans…this is a very high probability event IMHO. While preclinical I expect this study will kick it in like Hocker did to win gold in Olympic record time to astonish the front runners in the men’s 1500 meter run.
Marketing 101 puts your cherished jewel first…Cytodyn is going after cancer in a big way. I am reminded of Scott Kelly’s comment: “I think we will be known as an oncology company.”
Cancer lanes in blue, inflammation in red…mix them together and you have purple…Tyrolian purple dye was the most cherished and expensive in the ancient world, reserved strictly for royal wealth and privilege. In due course Leronlimab will be clothed in the same awe.
28
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Taking New Strides in Epilepsy Treatment Today, we’ve got SK Biopharmaceuticals banging on the FDA’s door with a pile of paperwork. They’re pushing for the green light on cenobamate to tackle primary generalized tonic-clonic (PGTC) seizures, plus expand its use to pediatric patients with the focal-onset seizure condition. Now, if you think it sounds like a big...
Continue Reading
Speed Matters in Renovation Projects You ever been locked in that eternal waiting game with a renovation project? It's a killer for the wallet. Chapter Renovation's digging into this mess, showing how dragging out a project can cost homeowners plenty more than they bargained for. They've been pushing an average completion time of 38 weeks. Compare that to the chilling...
Continue Reading
Unearthing the Hidden Struggle of PAH The American Lung Association (ALA) is getting loud about a quiet killer—pulmonary arterial hypertension (PAH) is in their spotlight this month, and it's about time. Documenting the horror stories of some 500 to 1,000 new PAH diagnoses each year in the U.S., the ALA is peeling back the blinds on a condition that's too often...
Continue Reading
Here's a Shift: Reliability Over Specs Alright, folks, buckle up because Ampace is shaking things up at EICMA Milan this year. While some are still yammering on about juicing up specs, Ampace is talking reliability. It's a bold move in the fast-evolving two-wheeler battery market, where everyone's been obsessed with horsepower and max speeds. The landscape's shifting...
Continue Reading
Reading Between the Lines of Prosperity You'd think the headlines scream gloom—job insecurity, a shaky economy, ridiculous basic cost hikes. Yet, against the odds like an underdog scrapping past the finish line, the Northwestern Mutual's Personal Prosperity Index crawled up to 71 out of 100, up by a humble three points since mid-year. Unlocking Prosperity in Chaotic...
Continue Reading
What's Stirring the Pot for Lululemon? Talk about a rollercoaster. Over here, Lululemon (NASDAQ:LULU) is navigating turbulent waters, facing a class action lawsuit for alleged securities fraud. Investors who bought into the brand between March 18, 2026, and September 3, 2026, are now watching their investments drop, following what's claimed as misleading trumpet calls...
Continue Reading
A Breakthrough for Ecobat Workers Man, when it comes to contracts, this recent deal at Ecobat is as game-changing as they get. A vote just ripped through like a hurricane, with 220 workers under Teamsters Local 986 eagerly ratifying a new three-year agreement that signals more than just a better payday. We're talking the largest wage boost these folks have clapped eyes on...
Continue Reading
The Midterm Aftermath: What Really Matters So the ballots are counted, and once again, the shiny chatter about midterms seemed to orbit more around wallet aches and foreign skirmishes than dusty border control debates. But, dig a bit deeper—like poking at a sore spot—and you'll find border security sitting patiently in the wings. Not gone, just waiting for its...
Continue Reading
Bluetooth HDT: The Next Leap in Connectivity Ceva's been in the game long before the rules were even set. With the introduction of Bluetooth High Data Throughput (HDT), they're not just playing; they're innovating. This tech doesn't just boost connectivity—it multiplies it, enhancing Bluetooth's reliability and energy efficiency while quadrupling data throughput. That's...
Continue Reading
Agthia's Q3 2026: A Balancing Act Between Growth and Costs When the going gets tough, the tough navigate strategic pivots. Agthia Group PJSC (AGTHIA:UH) isn't just sitting back and watching; they're charging ahead. They've rolled out their Q3 figures and, boy, it's a mix of hurdles and high jumps. With a 14.4% spike in revenue to AED 1.3 billion, it's clear they're not...
Continue Reading
Top 5 Most Recently Viewed Articles
Market Overview and Stock Movements The U.S. stock market experienced a mixed day as traders gauged the recent economic indicators and their implications on financial performance. The Nasdaq Composite stood out with a notable gain of approximately 150 points, reflecting a 0.70% increase to reach 21,851.83. Meanwhile, the Dow Jones Industrial Average faced a slight...
Continue Reading
AS Tallink Grupp's March and First Quarter Performance Overview In a recent report, AS Tallink Grupp announced their transportation statistics for March and the first quarter of the year. The company, known for its passenger and cargo transportation services, has experienced significant changes in its performance metrics. Passenger Transportation Insights For the month of...
Continue Reading
U.S. Stock Market Overview This morning, the stock market in the U.S. registered mixed results, creating a patchwork of fortunes among various sectors. The Dow Jones index recorded a drop of over 50 points, showcasing the volatility present in the financial markets. Market Indices Performance Current Status After the market opened, the Dow noted a decline of 0.16%,...
Continue Reading
Wolters Kluwer's Recent Share Buyback Program Wolters Kluwer, a global leader in professional information solutions, has been actively engaging in a share buyback program aimed at enhancing shareholder value. From July 17 to July 23, 2025, the company repurchased 190,651 ordinary shares at an impressive total cost of €26.6 million, resulting in an average share price of...
Continue Reading
Revolutionizing Agriculture Through Biofertilizers In today's world, where concerns about climate change grow more pressing, the agricultural sector is being called to action. Sustainable practices that not only maintain productivity but also contribute positively to the environment are increasingly crucial. Biofertilizers are emerging as key players in this initiative,...
Continue Reading